Dual-phase PET-CT to differentiate [18F]Fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer.
<h4>Purpose</h4>To investigate whether time-trends of enhanced [(18)F]Fluoromethylcholine ([(18)F]FCH) in lymph nodes (LN) of prostate cancer (PCa) patients can help to discriminate reactive from malignant ones, and whether single time point standardized uptake value (SUV) measurements a...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/85a3e7eff1754b0d8a4f0089296120b7 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:85a3e7eff1754b0d8a4f0089296120b7 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:85a3e7eff1754b0d8a4f0089296120b72021-11-18T08:10:23ZDual-phase PET-CT to differentiate [18F]Fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer.1932-620310.1371/journal.pone.0048430https://doaj.org/article/85a3e7eff1754b0d8a4f0089296120b72012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23119014/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Purpose</h4>To investigate whether time-trends of enhanced [(18)F]Fluoromethylcholine ([(18)F]FCH) in lymph nodes (LN) of prostate cancer (PCa) patients can help to discriminate reactive from malignant ones, and whether single time point standardized uptake value (SUV) measurements also suffice.<h4>Procedures</h4>25 PCa patients with inguinal (presumed benign) and enlarged pelvic LN (presumed malignant) showing enhanced [(18)F]FCH uptake at dual-phase PET-CT were analyzed. Associations between LN status (benign versus malignant) and SUV(max) and SUV(meanA50), determined at 2 min (early) and 30 min (late) post injection, were assessed. We considered two time-trends of [(18)F]FCH uptake: type A (SUV early > SUV late) and type B (SUV late ≥ SUV early). Histopathology and/or follow-up were used to confirm the assumption that LN with type A pattern are benign, and LN with type B pattern malignant.<h4>Results</h4>Analysis of 54 nodes showed that LN status, time-trends, and 'late' (30 min p.i.) SUV(max) and SUV(meanA50) parameters were strongly associated (P<0.0001). SUV(max) relative difference was the best LN status predictor. All but one inguinal LN showed a decreasing [(18)F]FCH uptake over time (pattern A), while 95% of the pelvic nodes presented a stable or increasing uptake (pattern B) type.<h4>Conclusions</h4>Time-trends of enhanced [(18)F]FCH uptake can help to characterize lymph nodes in prostate cancer patients. Single time-point SUV measurements, 30 min p.i., may be a reasonable alternative for predicting benign versus malignant status of lymph nodes, but this remains to be validated in non-enlarged pelvic lymph nodes.Daniela E Oprea-LagerAndrew D VincentReindert J A van MoorselaarWinald R GerritsenAlfons J M van den EertweghJonas ErikssonRonald BoellaardOtto S HoekstraPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 10, p e48430 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Daniela E Oprea-Lager Andrew D Vincent Reindert J A van Moorselaar Winald R Gerritsen Alfons J M van den Eertwegh Jonas Eriksson Ronald Boellaard Otto S Hoekstra Dual-phase PET-CT to differentiate [18F]Fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer. |
| description |
<h4>Purpose</h4>To investigate whether time-trends of enhanced [(18)F]Fluoromethylcholine ([(18)F]FCH) in lymph nodes (LN) of prostate cancer (PCa) patients can help to discriminate reactive from malignant ones, and whether single time point standardized uptake value (SUV) measurements also suffice.<h4>Procedures</h4>25 PCa patients with inguinal (presumed benign) and enlarged pelvic LN (presumed malignant) showing enhanced [(18)F]FCH uptake at dual-phase PET-CT were analyzed. Associations between LN status (benign versus malignant) and SUV(max) and SUV(meanA50), determined at 2 min (early) and 30 min (late) post injection, were assessed. We considered two time-trends of [(18)F]FCH uptake: type A (SUV early > SUV late) and type B (SUV late ≥ SUV early). Histopathology and/or follow-up were used to confirm the assumption that LN with type A pattern are benign, and LN with type B pattern malignant.<h4>Results</h4>Analysis of 54 nodes showed that LN status, time-trends, and 'late' (30 min p.i.) SUV(max) and SUV(meanA50) parameters were strongly associated (P<0.0001). SUV(max) relative difference was the best LN status predictor. All but one inguinal LN showed a decreasing [(18)F]FCH uptake over time (pattern A), while 95% of the pelvic nodes presented a stable or increasing uptake (pattern B) type.<h4>Conclusions</h4>Time-trends of enhanced [(18)F]FCH uptake can help to characterize lymph nodes in prostate cancer patients. Single time-point SUV measurements, 30 min p.i., may be a reasonable alternative for predicting benign versus malignant status of lymph nodes, but this remains to be validated in non-enlarged pelvic lymph nodes. |
| format |
article |
| author |
Daniela E Oprea-Lager Andrew D Vincent Reindert J A van Moorselaar Winald R Gerritsen Alfons J M van den Eertwegh Jonas Eriksson Ronald Boellaard Otto S Hoekstra |
| author_facet |
Daniela E Oprea-Lager Andrew D Vincent Reindert J A van Moorselaar Winald R Gerritsen Alfons J M van den Eertwegh Jonas Eriksson Ronald Boellaard Otto S Hoekstra |
| author_sort |
Daniela E Oprea-Lager |
| title |
Dual-phase PET-CT to differentiate [18F]Fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer. |
| title_short |
Dual-phase PET-CT to differentiate [18F]Fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer. |
| title_full |
Dual-phase PET-CT to differentiate [18F]Fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer. |
| title_fullStr |
Dual-phase PET-CT to differentiate [18F]Fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer. |
| title_full_unstemmed |
Dual-phase PET-CT to differentiate [18F]Fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer. |
| title_sort |
dual-phase pet-ct to differentiate [18f]fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2012 |
| url |
https://doaj.org/article/85a3e7eff1754b0d8a4f0089296120b7 |
| work_keys_str_mv |
AT danielaeoprealager dualphasepetcttodifferentiate18ffluoromethylcholineuptakeinreactiveandmalignantlymphnodesinpatientswithprostatecancer AT andrewdvincent dualphasepetcttodifferentiate18ffluoromethylcholineuptakeinreactiveandmalignantlymphnodesinpatientswithprostatecancer AT reindertjavanmoorselaar dualphasepetcttodifferentiate18ffluoromethylcholineuptakeinreactiveandmalignantlymphnodesinpatientswithprostatecancer AT winaldrgerritsen dualphasepetcttodifferentiate18ffluoromethylcholineuptakeinreactiveandmalignantlymphnodesinpatientswithprostatecancer AT alfonsjmvandeneertwegh dualphasepetcttodifferentiate18ffluoromethylcholineuptakeinreactiveandmalignantlymphnodesinpatientswithprostatecancer AT jonaseriksson dualphasepetcttodifferentiate18ffluoromethylcholineuptakeinreactiveandmalignantlymphnodesinpatientswithprostatecancer AT ronaldboellaard dualphasepetcttodifferentiate18ffluoromethylcholineuptakeinreactiveandmalignantlymphnodesinpatientswithprostatecancer AT ottoshoekstra dualphasepetcttodifferentiate18ffluoromethylcholineuptakeinreactiveandmalignantlymphnodesinpatientswithprostatecancer |
| _version_ |
1718422119755284480 |